H2-Receptor Antagonist Monotherapy is the Appropriate Alternative
In a patient with functional dyspepsia who declines PPIs, use an H2-receptor antagonist alone—do not combine it with sucralfate. The 2022 British Society of Gastroenterology guidelines explicitly recommend H2-receptor antagonists as an efficacious first-line treatment for functional dyspepsia, while sucralfate has no established role in this condition 1.
Why H2-Receptor Antagonists Work
H2-receptor antagonists are a reasonable alternative when patients refuse PPIs, though they are less effective. The BSG guidelines rate them as "weak recommendation, low quality evidence" compared to PPIs' "strong recommendation, high quality evidence" 1. A systematic review demonstrated that H2-receptor antagonists achieve a 22% relative risk reduction in dyspepsia symptoms (95% CI: 7-35%) and are well-tolerated 2.
Why Sucralfate Should Not Be Used
Sucralfate has no evidence supporting its use in functional dyspepsia. The evidence base for sucralfate is limited to duodenal ulcer disease, not functional dyspepsia 3. The systematic review by Moayyedi et al. found that sucralfate was not statistically significantly superior to placebo for non-ulcer dyspepsia 2. Notably, the BSG guidelines make no mention of sucralfate as a treatment option for functional dyspepsia across any line of therapy 1.
Why Combination Therapy is Not Recommended
There is no evidence supporting the combination of H2-receptor antagonists with sucralfate for functional dyspepsia. The BSG guidelines identify combination therapy as a research gap, specifically mentioning "dual therapy with histamine-1 and histamine-2 receptor antagonists" as needing investigation—but notably do not mention sucralfate combinations 1.
Important Drug Interaction Concern
The FDA label warns that sucralfate reduces the bioavailability of multiple medications, including ranitidine and cimetidine (both H2-receptor antagonists) 3. While dosing the H2-antagonist 2 hours before sucralfate can mitigate this interaction, this adds complexity without proven benefit in functional dyspepsia.
Historical drug utilization reviews from the 1980s-1990s consistently found H2-antagonist plus sucralfate combination therapy to be inappropriate in most cases, with one study showing only 1 of 109 treatment courses met appropriateness criteria 4.
Practical Treatment Algorithm
Step 1: Start H2-receptor antagonist monotherapy (e.g., famotidine 20 mg twice daily or ranitidine equivalent)
Step 2: If inadequate response after 4-8 weeks, consider:
- Switching to a prokinetic agent (if available in your region)
- Adding a tricyclic antidepressant as a neuromodulator (e.g., amitriptyline 10 mg at bedtime, titrate to 30-50 mg) 1
- Revisiting the PPI discussion with careful explanation of the rationale
Step 3: For refractory symptoms, refer to gastroenterology for specialist management 1
Common Pitfalls to Avoid
- Do not use sucralfate for functional dyspepsia—it is indicated only for duodenal ulcers
- Do not combine H2-antagonists with sucralfate without clear evidence of peptic ulcer disease
- Be aware that H2-receptor antagonists can develop tachyphylaxis (tolerance) with prolonged use 5
- Remember that functional dyspepsia is a brain-gut disorder; acid suppression alone may be insufficient, and neuromodulators (TCAs) are evidence-based second-line therapy 1, 6
The patient's refusal of PPIs should prompt exploration of their concerns, as PPIs remain the most effective acid-suppressive therapy. However, if they remain adamant, H2-receptor antagonist monotherapy is the evidence-based alternative 1.